Bioventus Inc Cash Flow Conversion Efficiency
Bioventus Inc cash flow conversion efficiency. Based on the latest financial reports, Bioventus Inc (BVS) has a cash flow conversion efficiency ratio of 0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($19.87 Million) by net assets ($277.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bioventus Inc (2014–2025)
Cash flow conversion efficiency of Bioventus Inc from 2014 to 2025. This chart illustrates how Bioventus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BVS share price today for real-time trading data and today's change.
Bioventus Inc Cash Flow Conversion Ratio Explained
Bioventus Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bioventus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioventus Inc ranked by their cash flow conversion efficiency. Also see BVS company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YD More Investments Ltd
TA:MRIN
|
-0.004x |
|
Ceigall India
NSE:CEIGALL
|
-0.081x |
|
Dan Hotels
TA:DANH
|
0.036x |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093
|
0.030x |
|
Shandong Link Science and Technology Co Ltd
SHE:001207
|
0.031x |
|
MainStay CBRE Global Infrastructure Megatrends Fund
NYSE:MEGI
|
N/A |
|
Shenzhen Riland Industry Co
SHE:300154
|
0.062x |
|
Jilin Yatai Group Co Ltd
SHG:600881
|
0.038x |
Annual Cash Flow Conversion Efficiency for Bioventus Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Bioventus Inc from 2014 to 2025. Review Bioventus Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $228.45 Million | $73.98 Million | 0.324x | +54.92% |
| 2024-12-31 | $185.60 Million | $38.80 Million | 0.209x | +201.21% |
| 2023-12-31 | $221.12 Million | $15.34 Million | 0.069x | +311.31% |
| 2022-12-31 | $412.22 Million | $-13.54 Million | -0.033x | -176.24% |
| 2021-12-31 | $533.79 Million | $22.99 Million | 0.043x | -91.35% |
| 2020-12-31 | $144.16 Million | $71.80 Million | 0.498x | +78.14% |
| 2019-12-31 | $145.62 Million | $40.71 Million | 0.280x | -10.12% |
| 2018-12-31 | $145.27 Million | $45.19 Million | 0.311x | +216.22% |
| 2015-12-31 | $192.34 Million | $18.92 Million | 0.098x | +15.56% |
| 2014-12-31 | $177.49 Million | $15.11 Million | 0.085x | -- |
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more